

Remarks

In the Notice of Allowance, the Examiner noted that claims 1 to 6 are allowed. By this amendment, claim 1 has been amended in order to disclaim three of the compounds which appear to have been disclosed in WO 95/03306, see specifically, compound nos. 452-1, 452-2 and 452-3, Table 16, page 35. Please note that all of these three compounds read on compound of formula (I) when R = fluorine, chlorine or bromine and when both of the two carbon-carbon bonds represented by ---- are single bonds. Thus it is respectfully submitted that no new subject matter has been inserted through these amendments. All of the amendments are fully supported by the specification. It is further submitted that claim 1, as amended, is still in condition for allowance, and claims 2-5 have already been allowed.

Supplemental Information Disclosure Statement

Applicants concurrently submit herewith a supplemental IDS along with Form 1449 which lists the above noted WO 95/03306 reference. Entry of which into record is respectfully requested. Applicants also request an initialed copy of Form 1449 for Applicants' records.

Conclusions

In view of the above Remarks, it is respectfully submitted that claim 1, as amended, and claims 2 to 6 are now in condition for allowance and the early issuance of this case is respectfully requested. In the event the Examiner wishes to contact the undersigned regarding any matter, please call (collect if necessary) the telephone number listed below.


As noted above, Applicants are concurrently filing a request for continued examination (RCE) with this submission along with a supplemental IDS. Applicants

Application Ser. No.: 10/500,015
Filing Date: June 23, 2004
Examiner: Owens, Amelia A.

request the Commissioner to charge these fees and any other fees that are deemed necessary due to this submission to Deposit Account No. **18-1982** for sanofi-aventis U.S. LLC, Bridgewater, NJ. Please credit any overpayment to Deposit Account No. **18-1982**.

October 30, 2006

Respectfully submitted,



Balaram Gupta, Ph. D., J. D.
Registration No. 40,009
Attorney for Applicants

Enclosures: RCE transmittal (1 page)
Supplemental IDS (3 pages)

sanofi-aventis U.S. LLC
US Patent Operations
Route #202-206 / P.O. Box 6800
MAIL CODE: BWD-303A
Bridgewater, NJ 08807-0800
Telephone: 908-231-3364
Telefax: 908-231-2626